Back to Cell Types

SJSA-1Homo sapiens (Human)Cancer cell line

Also known as: OsA, OSA, Os-A, OSACL, OsACL, OSA-CL, OsA-CL, SJSA, SJSA1, SISA, SJSA2

🤖 AI SummaryBased on 15 publications

Quick Overview

SJSA-1 is a human osteosarcoma cell line used in cancer research.

Detailed Summary

SJSA-1 is a human osteosarcoma cell line derived from a bone tumor. It is widely used in research to study the genetic and molecular mechanisms of osteosarcoma. This cell line has been characterized in multiple studies for its genomic alterations, including chromosomal abnormalities and gene expression profiles. Research on SJSA-1 has contributed to understanding the complexities of osteosarcoma biology and potential therapeutic targets. The cell line is part of several large-scale studies, including the Cancer Cell Line Encyclopedia (CCLE) and other genomic projects, providing valuable data for cancer research.

Research Applications

Genomic studiesDrug screeningMolecular mechanism research

Key Characteristics

Chromosomal abnormalitiesGene expression profilingOsteosarcoma model

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1697
Species	Homo sapiens (Human)
Tissue Source	Bone, femur[UBERON:UBERON_0000981]

Donor Information

Age	19
Age Category	Adult
Sex	Male
Race	black_or_african_american

Disease Information

Disease	Osteosarcoma
Lineage	Bone
Subtype	Osteosarcoma
OncoTree Code	OS

DepMap Information

Source Type	ATCC
Source ID	ACH-000748_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationNone reported	TP53	-	-	-	PubMed=19787792
MutationSimple	NRAS	p.Gln61Lys (c.181C>A)	Unspecified	Acquired during resistance selection process	PubMed=26214590
MutationSimple	KRAS	p.Gln61His (c.183A>T)	Unspecified	-	DOI=10.6342/NTU.2004.01000
Gene deletion	CDKN2A	-	Homozygous	Possible	PubMed=26870271

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

10,11

D13S317

12,13

D16S539

9,10

D18S51

15,17

D19S433

14.2,15

D21S11

28,33.2

D2S1338

21,25

D3S1358

16,17

D5S818

12

D7S820

9,11

D8S1179

13,15

FGA

22,23

Penta D

2.2,10

Penta E

11,14

SE33

21.2,27.2

TH01

7,9

TPOX

8,9

vWA

19

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Identification of a novel gene fusion in ALT positive osteosarcoma.";

Matschulat A., Labadorf A., Flynn R.L.

Oncotarget 9:32868-32880(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.

Harris E., Monks A., Morris J.

Mol. Cancer Ther. 14:2452-2462(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.

Myklebost O., Meza-Zepeda L.A.

PLoS ONE 7:E48262-E48262(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.

Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.

Lab. Invest. 91:1195-1205(2011).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.

Buerger H., Aigner T., Gabbert H.E., Poremba C.

Genes Chromosomes Cancer 49:40-51(2010).

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.

Myklebost O.

Int. J. Cancer 121:199-205(2007).

Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.

Gabbert H.E., Poremba C.

Cancer Res. 64:3395-3405(2004).

Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.

Poremba C.

Cancer Genet. Cytogenet. 140:145-152(2003).

Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.

Rauscher F.J. 3rd, Emanuel B.S., Rovera G., Barr F.G.

Nat. Genet. 5:230-235(1993).

Amplification of the gli gene in childhood sarcomas.";

Roberts W.M., Douglass E.C., Peiper S.C., Houghton P.J., Look A.T.

Cancer Res. 49:5407-5413(1989).

Web Resources